inclusion criteria: * availability of pis informed consent form signed and dated by a patient. * male and female subjects aged 18 to 80 inclusive as of the time of signing the pis informed consent form. * confirmed covid-19 at screening stage: positive for sars-cov-2 rna laboratory test with nucleic acid amplification techniques (naat) or sars-cov-2 antigen with immunochromatographic assay. * sars-cov-2 test results obtained up to 5 days prior to randomization may be taken into account upon availability of supporting documentation. * mild or moderate sars-cov-2 induced infection. * at least one of the following covid-19 symptoms as of the time of screening and randomization: nasal congestion or rhinitis; sore throat; dyspnoea or respiratory distress on exertion; cough; tiredness; pain in muscles or throughout the body; headache; chills; fever (body temperature \> 38 ⁰с); nausea; vomiting; diarrhoea; anosmia; ageusia. * disease onset (first symptom) within not more than 5 days prior to randomization * the patient agrees and is able to take oral drug products. * patient's consent to use reliable contraception methods during the entire study and for 3 weeks after the end of the study. reliable contraception methods are: sexual abstinence, the use of a condom combined with a spermicidal agent. * female subjects incapable of bearing children (history: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as male subjects with infertility or a history of vasectomy may participate in the study.

inclusion criteria: * availability of pis informed consent form signed and dated by a patient. * male and female subjects aged 18 to 80 inclusive as of the time of signing the pis informed consent form. * confirmed covid-19 at screening stage: positive for sars-cov-2 rna laboratory test with nucleic acid amplification techniques (naat) or sars-cov-2 antigen with immunochromatographic assay. * sars-cov-2 test results obtained up to 5 days prior to randomization may be taken into account upon availability of supporting documentation. * mild or moderate sars-cov-2 induced infection. * at least one of the following covid-19 symptoms as of the time of screening and randomization: nasal congestion or rhinitis; sore throat; dyspnoea or respiratory distress on exertion; cough; tiredness; pain in muscles or throughout the body; headache; chills; fever (body temperature \> 38 ⁰с); nausea; vomiting; diarrhoea; anosmia; ageusia. * disease onset (first symptom) within not more than 5 days prior to randomization * the patient agrees and is able to take oral drug products. * patient's consent to use reliable contraception methods during the entire study and for 3 weeks after the end of the study. reliable contraception methods are: sexual abstinence, the use of a condom combined with a spermicidal agent. * female subjects incapable of bearing children (history: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as male subjects with infertility or a history of vasectomy may participate in the study.

inclusion criteria: availability of pis informed consent form signed and dated by a patient. male and female subjects aged 18 to 80 inclusive as of the time of signing the pis informed consent form. confirmed covid-19 at screening stage: positive for sars-cov-2 rna laboratory test with nucleic acid amplification techniques (naat) or sars-cov-2 antigen with immunochromatographic assay. sars-cov-2 test results obtained up to 5 days prior to randomization may be taken into account upon availability of supporting documentation. mild or moderate sars-cov-2 induced infection. at least one of the following covid-19 symptoms as of the time of screening and randomization: nasal congestion or rhinitis; sore throat; dyspnoea or respiratory distress on exertion; cough; tiredness; pain in muscles or throughout the body; headache; chills; fever (body temperature > 38 ⁰с); nausea; vomiting; diarrhoea; anosmia; ageusia. disease onset (first symptom) within not more than 5 days prior to randomization the patient agrees and is able to take oral drug products. patient's consent to use reliable contraception methods during the entire study and for 3 weeks after the end of the study. reliable contraception methods are: sexual abstinence, the use of a condom combined with a spermicidal agent. female subjects incapable of bearing children (history: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as male subjects with infertility or a history of vasectomy may participate in the study.

inclusion criteria: availability of pis informed consent form signed and dated by a patient. male and female subjects aged 18 to 80 inclusive as of the time of signing the pis informed consent form. confirmed covid-19 at screening stage: positive for sars-cov-2 rna laboratory test with nucleic acid amplification techniques (naat) or sars-cov-2 antigen with immunochromatographic assay. sars-cov-2 test results obtained up to 5 days prior to randomization may be taken into account upon availability of supporting documentation. mild or moderate sars-cov-2 induced infection. at least one of the following covid-19 symptoms as of the time of screening and randomization: nasal congestion or rhinitis; sore throat; dyspnoea or respiratory distress on exertion; cough; tiredness; pain in muscles or throughout the body; headache; chills; fever (body temperature > 38 ⁰с); nausea; vomiting; diarrhoea; anosmia; ageusia. disease onset (first symptom) within not more than 5 days prior to randomization the patient agrees and is able to take oral drug products. patient's consent to use reliable contraception methods during the entire study and for 3 weeks after the end of the study. reliable contraception methods are: sexual abstinence, the use of a condom combined with a spermicidal agent. female subjects incapable of bearing children (history: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as male subjects with infertility or a history of vasectomy may participate in the study.